

# UBS (CH) Institutional Fund – Equities UK Passive II I-X

## Portrait

- Regulation / Supervision: CISA / FINMA (Funds for qualified investors).
- Authorised investors: pension funds, insurance companies, family offices and institutional investors under CISA.
- Investments: Equity securities of companies included in the MSCI United Kingdom Index.
- No investments in securities on the recommendation list for the exclusion of SVVK-ASIR ([www.svk-asir.ch](http://www.svk-asir.ch)) and controversial weapons.
- Portfolio is passively managed and aims to replicate the performance of the benchmark.
- Currency exposure: in line with securities portfolio.
- Securities lending: not permitted.
- Use of derivatives: permitted under BVV2.
- All investments are subject to market fluctuations. Every fund has specific risks, which can significantly increase under unusual market conditions. Please consult your client advisor for more information on the investment risks of this product.

Securities no.	56,650,910
ISIN	CH0566509102
Reuters symbol	–
Bloomberg Ticker	EQUPIX SW
Currency of account	CHF
Issue/redemption	daily
Admin/Custody fees	none
Dilution Levy in Favour of the Fund in/out	0.49%/0.02%
Benchmark	MSCI United Kingdom (net div. reinv.) in CHF

## Current data

Net asset value 31.1.2025	CHF	1,640.69
– high last 12 months	CHF	1,640.69
– low last 12 months	CHF	1,358.37
Assets of the unit class in m	CHF	399.44
Fund assets in m	CHF	1,135.88
Last distribution		reinvested

## Key risk figures (annualised)

	2 years	3 years
Tracking error	0.06%	0.06%
Beta	1.00	1.00
Correlation	1.00	1.00
Total risk	10.03%	13.13%
Sharpe ratio	0.80	0.38
Risk-free rate (2 years) = 1.34%		

The statistical ratios were calculated on the basis of logarithmic returns.


## Sectors (in %)

	Fund	Benchmark
Energy	11.55	11.54
Materials and supplies	6.96	6.97
Industrials	13.77	13.78
Consumer discretionary	5.86	5.86
Consumer staples	16.75	18.34
Health care	13.73	12.15
Financial system	22.64	22.66
IT	1.23	1.23
Telecommunication services	2.54	2.53
Utilities	4.28	4.28
Real estate	0.66	0.66
Others	0.03	0.00
<b>Total</b>	<b>100.00</b>	<b>100.00</b>

## Performance (in %, net of fees)

	Fund	Benchmark
02.2024	2.68	2.67
03.2024	6.84	6.86
04.2024	3.74	3.75
05.2024	1.87	1.89
06.2024	-2.14	-2.14
07.2024	2.06	2.07
08.2024	-0.41	-0.41
09.2024	-0.30	-0.32
10.2024	-3.12	-3.12
11.2024	3.29	3.30
12.2024	0.02	0.03
01.2025	5.42	5.42
2025 YTD	5.42	5.42
2024	15.72	15.79
2023	3.69	3.79
2022	-3.38	-3.37
2021	22.09	22.14
2020 (since launch 10.2020)	18.75	18.78
Ø p.a. 2 years	9.36	9.45
Ø p.a. 3 years	5.83	5.89
since end of fund launch month		
10.2020	77.19	77.61

## Indexed performance



— UBS (CH) Institutional Fund – Equities UK Passive II I-X  
— MSCI United Kingdom (net div. reinv.) in CHF

Past performance is no guarantee of future trends. The performance shown does not take account of any commissions and costs charged when subscribing to and redeeming units.

## 10 largest positions (in %)

	Fund	Benchmark
AstraZeneca PLC	8.65	8.65
Shell PLC	8.19	0.00
HSBC Holdings PLC	7.57	7.58
Unilever PLC	5.66	5.66
RELX PLC	3.69	3.69
<b>Top 5</b>	<b>33.76</b>	<b>25.58</b>
BP PLC	3.36	3.36
British American Tobacco PLC	3.14	3.13
GSK PLC	2.87	2.87
London Stock Exchange Group PLC	2.83	2.83
Rio Tinto PLC	2.71	2.71
<b>Top 10</b>	<b>48.67</b>	<b>40.48</b>

# UBS (CH) Institutional Fund – Equities UK Passive II I-X

**For marketing and information purposes by UBS.** For professional clients / qualified investors only. UBS funds under Swiss law. Arrangements for marketing fund units mentioned in this document may be terminated at the initiative of the management company of the fund(s). Before investing in a product please read the latest prospectus and key information document or similar legal documentation carefully and thoroughly. Any decision to invest should take into account all the characteristics or objectives of the product as described in its prospectus, or similar legal documentation. Investors are acquiring units or shares in a fund, and not in a given underlying asset such as building or shares of a company. The information and opinions contained in this document have been compiled or arrived at based upon information obtained from sources believed to be reliable and in good faith, but is not guaranteed as being accurate, nor is it a complete statement or summary of the securities, markets or developments referred to in the document. Members of the UBS Group may have a position in and may make a purchase and / or sale of any of the securities or other financial instruments mentioned in this document. Units of UBS funds mentioned herein may not be eligible for sale in all jurisdictions or to certain categories of investors and may not be offered, sold or delivered in the United States. The information mentioned herein is not intended to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. Past performance is not a reliable indicator of future results. The calculated performance takes all costs on the product level into consideration (ongoing costs). The entry and exit costs, which would have a negative impact on the performance, are not taken into consideration. If whole or part of the total costs to be paid is different from your reference currency, the costs may increase or decrease as a result of currency and exchange rate fluctuations. Commissions and costs have a negative impact on the investment and on the expected returns. If the currency of a financial product or financial service is different from your reference currency, the return can increase or decrease as a result of currency and exchange rate fluctuations. This information pays no regard to the specific or future investment objectives, financial or tax situation or particular needs of any specific recipient. Future performance is subject to taxation which depends on the personal situation of each investor and which may change in the future. The details and opinions contained in this document are provided by UBS without any guarantee or warranty and are for the recipient's personal use and information purposes only. This document may not be reproduced, redistributed or republished for any purpose without the written permission of UBS Asset Management Switzerland AG or a local affiliated company. Source for all data and charts (if not indicated otherwise): UBS Asset Management. This document contains statements that constitute "forward-looking statements", including, but not limited to, statements relating to our future business development. While these forward-looking statements represent our judgments and future expectations concerning the development of our business, a number of risks, uncertainties and other important factors could cause actual developments and results to differ materially from our expectations.

**Additional information to investors in specific countries: Switzerland:** Only occupational pension schemes domiciled in Switzerland, their asset managers (for the assets of these institutions) and other investment foundations are eligible investors in investment foundations, in accordance with the Ordinance on Investment Foundations (ASV). Prospectuses, key information document, the articles of association or the management regulations as well as annual and semi-annual reports of UBS funds are available in a language required by the local applicable law free of charge from UBS Asset Management Switzerland AG, c/o UBS AG, Bahnhofstrasse 45, 8001 Zürich or from UBS Fund Management (Switzerland) AG, P.O. Box, CH-4002 Basel. A summary of investor rights in English can be found online at [www.ubs.com/funds-regulatoryinformation](http://www.ubs.com/funds-regulatoryinformation). More explanations of financial terms can be found at [www.ubs.com/am-glossary](http://www.ubs.com/am-glossary).

© UBS 2025. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.